Clinical Trial Update: A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of rhuMAb Beta7 in Patients With Ulcerative Colitis [Phase 1]

View source ↗

Summary

A completed Phase 1 trial evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of rhuMAb Beta7 in patients with ulcerative colitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• rhuMAb Beta7

Snippet

Sponsor: Genentech, Inc. | Conditions: Ulcerative Colitis | Phase 1 | Status: COMPLETED